“…Improvement with infliximab has been reported with metastatic Crohn's disease and Crohn'sassociated spondyloarthropathy, pancreatitis, pulmonary disease, ocular disease (uveitis), and cutaneous disease (psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa). [18][19][20][21][22][23][24][25][26][27][28] Many patients reported were refractory to other therapies, and some have required infliximab as maintenance for their extraintestinal manifestations. Infliximab has been shown to be efficacious for spondyloarthrpathies and in particular, ankylosing spondylitis in patients without a diagnosis of Crohn's disease.…”